Cargando…

Antitumor effect of gemcitabine-loaded albumin nanoparticle on gemcitabine-resistant pancreatic cancer induced by low hENT1 expression

PURPOSE: Gemcitabine is currently the standard first-line chemotherapeutic drug for treating pancreatic cancer. However, many factors can contribute to gemcitabine resistance. One of the most important reasons is the low hENT1 expression. In this study, we tested the antitumor effect of gemcitabine-...

Descripción completa

Detalles Bibliográficos
Autores principales:	Guo, Zhongyi, Wang, Feng, Di, Yang, Yao, Lie, Yu, Xinzhe, Fu, Deliang, Li, Ji, Jin, Chen
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2018
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6122898/ https://www.ncbi.nlm.nih.gov/pubmed/30214194 http://dx.doi.org/10.2147/IJN.S166769

Ejemplares similares

hENT1’s role in adjuvant intra-arterial gemcitabine-based chemotherapy for resectable pancreatic cancer patients
por: Wang, Wei, et al.
Publicado: (2023)

Roles for hENT1 and dCK in gemcitabine sensitivity and malignancy of meningioma
por: Yamamoto, Masahiro, et al.
Publicado: (2021)

hENT1 Predicts Benefit from Gemcitabine in Pancreatic Cancer but Only with Low CDA mRNA
por: Aughton, Karen, et al.
Publicado: (2021)

ET-7 Roles for hENT1 and dCK in gemcitabine sensitivity and malignancy of meningioma
por: Yamamoto, Masahiro, et al.
Publicado: (2021)

An in vitro and in vivo study of gemcitabine-loaded albumin nanoparticles in a pancreatic cancer cell line
por: Yu, Xinzhe, et al.
Publicado: (2015)

hENT-1 Expression and Localization Predict Outcome After Adjuvant Gemcitabine in Resected Cholangiocarcinoma Patients
por: Meijer, Laura L., et al.
Publicado: (2016)

Gemcitabine-Loaded Albumin Nanoparticle Exerts An Antitumor Effect on Gemcitabine-Resistant Pancreatic Cancer Cells Induced by MDR1 and MRP1 Overexpression in Vitro
por: Kong, Lei, et al.
Publicado: (2022)

hENT1 Testing in Pancreatic Ductal Adenocarcinoma: Are We Ready? A Multimodal Evaluation of hENT1 Status
por: Raffenne, Jerome, et al.
Publicado: (2019)

Combination treatment with hENT1 and miR-143 reverses gemcitabine resistance in triple-negative breast cancer
por: Xi, Yue, et al.
Publicado: (2022)

Human equilibrative nucleoside transporter 1 (hENT1) expression as a predictive biomarker for gemcitabine chemotherapy in biliary tract cancer
por: Kim, Jaihwan, et al.
Publicado: (2018)

Gemcitabine-loaded albumin nanospheres (GEM-ANPs) inhibit PANC-1 cells in vitro and in vivo
por: Li, Ji, et al.
Publicado: (2013)

Expression of dihydropyrimidine dehydrogenase (DPD) and hENT1 predicts survival in pancreatic cancer
por: Elander, N. O., et al.
Publicado: (2018)

A predictive analysis of the SP120 and 10D7G2 antibodies for human equilibrative nucleoside transporter 1 (hENT1) in pancreatic ductal adenocarcinoma treated with adjuvant gemcitabine
por: Kalloger, Steve E, et al.
Publicado: (2017)

Human Equilibrative Nucleoside Transporter 1 (hENT1) in Pancreatic Adenocarcinoma: Towards Individualized Treatment Decisions
por: Spratlin, Jennifer L., et al.
Publicado: (2010)

Triple-functional albumin-based nanoparticles for combined chemotherapy and photodynamic therapy of pancreatic cancer with lymphatic metastases
por: Yu, Xinzhe, et al.
Publicado: (2017)

Prognostic effect of hENT1, dCK and HuR expression by morphological type in periampullary adenocarcinoma, including pancreatic cancer
por: Elebro, Jacob, et al.
Publicado: (2016)

FBW7 increases the chemosensitivity of pancreatic cancer cells to gemcitabine through upregulation of ENT1
por: Hu, Qiangsheng, et al.
Publicado: (2017)

Decreased erythrocyte nucleoside transport and hENT1 transporter expression in glucose 6-phosphate dehydrogenase deficiency
por: Al-Ansari, Mohammad, et al.
Publicado: (2015)

Huaier increases the antitumor effect of gemcitabine on pancreatic cancer in vitro and in vivo
por: Chen, Tao, et al.
Publicado: (2021)

Synergistic Antitumoral Effect of Epigenetic Inhibitors and Gemcitabine in Pancreatic Cancer Cells
por: Maietta, Immacolata, et al.
Publicado: (2022)

Bidirectional transport of 2-chloroadenosine by equilibrative nucleoside transporter 4 (hENT4): Evidence for allosteric kinetics at acidic pH
por: Tandio, David, et al.
Publicado: (2019)

Gold Nanoparticles sensitize pancreatic cancer cells to gemcitabine
por: Huai, Yanyan, et al.
Publicado: (2019)

Prognostic and predictive value of human equilibrative nucleoside transporter 1 (hENT1) in extrahepatic cholangiocarcinoma: a translational study
por: Boyd, Lenka N. C., et al.
Publicado: (2023)

Up-regulation of HER2 by gemcitabine enhances the antitumor effect of combined gemcitabine and trastuzumab emtansine treatment on pancreatic ductal adenocarcinoma cells
por: Kan, Shin, et al.
Publicado: (2015)

A Liposomal Gemcitabine, FF-10832, Improves Plasma Stability, Tumor Targeting, and Antitumor Efficacy of Gemcitabine in Pancreatic Cancer Xenograft Models
por: Matsumoto, Takeshi, et al.
Publicado: (2021)

Are ENT1/ENT1, NOTCH3, and miR-21 Reliable Prognostic Biomarkers in Patients with Resected Pancreatic Adenocarcinoma Treated with Adjuvant Gemcitabine Monotherapy?
por: Jiraskova, Lucie, et al.
Publicado: (2019)

Pancreatic Cancer Chemoresistance to Gemcitabine
por: Amrutkar, Manoj, et al.
Publicado: (2017)

Establishment and characterization of the gemcitabine-resistant human pancreatic cancer cell line SW1990/gemcitabine
por: Yu, Yue, et al.
Publicado: (2019)

SKM-1细胞地西他滨耐药机制中hENT1功能的研究
Publicado: (2015)

Gestational Diabetes—Placental Expression of Human Equilibrative Nucleoside Transporter 1 (hENT1): Is Delayed Villous Maturation an Adaptive Pattern?
por: Giacometti, Cinzia, et al.
Publicado: (2023)

Mechanistic studies of Gemcitabine-loaded nanoplatforms in resistant pancreatic cancer cells
por: Papa, Anne-Laure, et al.
Publicado: (2012)

Gemcitabine-loaded PLGA-PEG immunonanoparticles for targeted chemotherapy of pancreatic cancer
por: Aggarwal, Sahil, et al.
Publicado: (2013)

Cytotoxicity of gemcitabine-loaded thermosensitive liposomes in pancreatic cancer cell lines
por: Affram, Kevin, et al.
Publicado: (2015)

Gemcitabine Conjugated Chitosan and Double Antibodies (Abc-GC-Gemcitabine Nanoparticles) Enhanced Cytoplasmic Uptake of Gemcitabine and Inhibit Proliferation and Metastasis In Human SW1990 Pancreatic Cancer Cells
por: Xiao, Jun, et al.
Publicado: (2017)

Gold Nanoparticles Synthesized by an Aqueous Extract of Codium tomentosum as Potential Antitumoral Enhancers of Gemcitabine
por: González-Ballesteros, Noelia, et al.
Publicado: (2022)

Albumin-bound paclitaxel and gemcitabine combination therapy in soft tissue sarcoma
por: Tian, Zhichao, et al.
Publicado: (2020)

Human equilibrative nucleoside transporter-1 (hENT1) and ribonucleotide reductase regulatory subunit M1 (RRM1) expression; do they have survival impact to pancreatic cancer?
por: Hwang, Dae Wook, et al.
Publicado: (2020)

Sequential therapy for pancreatic cancer by losartan- and gemcitabine-loaded magnetic mesoporous spheres
por: Li, Yanjun, et al.
Publicado: (2019)

Gemcitabine chemoresistance and molecular markers associated with gemcitabine transport and metabolism in human pancreatic cancer cells
por: Nakano, Y, et al.
Publicado: (2007)

Gemcitabine and oxaliplatin (GEMOX) in gemcitabine refractory advanced pancreatic adenocarcinoma: a phase II study
por: Demols, A, et al.
Publicado: (2006)

Cannot write session to /tmp/vufind_sessions/sess_f9l2dcsgg9pem38ppfj0639e1s